WO2005042561A3 - Neural regeneration peptides and methods of use - Google Patents

Neural regeneration peptides and methods of use Download PDF

Info

Publication number
WO2005042561A3
WO2005042561A3 PCT/US2004/036203 US2004036203W WO2005042561A3 WO 2005042561 A3 WO2005042561 A3 WO 2005042561A3 US 2004036203 W US2004036203 W US 2004036203W WO 2005042561 A3 WO2005042561 A3 WO 2005042561A3
Authority
WO
WIPO (PCT)
Prior art keywords
neural
methods
nrp compounds
neuronal
nrps
Prior art date
Application number
PCT/US2004/036203
Other languages
French (fr)
Other versions
WO2005042561A2 (en
Inventor
Frank Sieg
Thorsten Gorba
Original Assignee
Neuren Pharmaceuticals Ltd
Frank Sieg
Thorsten Gorba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuren Pharmaceuticals Ltd, Frank Sieg, Thorsten Gorba filed Critical Neuren Pharmaceuticals Ltd
Priority to JP2006538375A priority Critical patent/JP5026083B2/en
Priority to EP04800514A priority patent/EP1685151A4/en
Publication of WO2005042561A2 publication Critical patent/WO2005042561A2/en
Publication of WO2005042561A3 publication Critical patent/WO2005042561A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)

Abstract

The invention discloses a family of peptides termed NRP compounds or NRPs that can promote neuronal migration, neurite outgrowth, neuronal proliferation, neural differentiation and/or neuronal survival, and provides compositions and methods for the use of NRPs in the treatment of brain injury and neurodegenerative disease. NRP compounds can induce neurons and neuroblasts to proliferate and migrate into areas of damage caused by acute brain injury or chronic neurodegenerative disease, such as exposure to toxins, stroke, trauma, nervous system infections, demyelinating diseases, dementias, and metabolic disorders. NRP compounds may be administered directly to a subject or to a subject's cells by a variety of means including orally, intraperitoneally, intravascularly, and directly into the nervous system of a patient. NRP compounds can be formulated into pharmaceutically acceptable dose forms for therapeutic use. Methods for detecting neural regeneration, neural proliferation, neural differentiation, neurite outgrowth and neural survival can be used to develop other neurally active agents.
PCT/US2004/036203 2003-10-31 2004-11-01 Neural regeneration peptides and methods of use WO2005042561A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2006538375A JP5026083B2 (en) 2003-10-31 2004-11-01 Nerve regeneration peptides and their use in the treatment of brain injury
EP04800514A EP1685151A4 (en) 2003-10-31 2004-11-01 Neural regeneration peptides and methods for their use in treatment of brain damage

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US51601803P 2003-10-31 2003-10-31
US60/516,018 2003-10-31
US58504104P 2004-07-02 2004-07-02
US60/585,041 2004-07-02
US61627104P 2004-10-05 2004-10-05
US60/616,271 2004-10-05

Publications (2)

Publication Number Publication Date
WO2005042561A2 WO2005042561A2 (en) 2005-05-12
WO2005042561A3 true WO2005042561A3 (en) 2006-10-12

Family

ID=34557374

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/036203 WO2005042561A2 (en) 2003-10-31 2004-11-01 Neural regeneration peptides and methods of use

Country Status (3)

Country Link
EP (1) EP1685151A4 (en)
JP (1) JP5026083B2 (en)
WO (1) WO2005042561A2 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121926A2 (en) * 2005-05-06 2006-11-16 Neuren Pharmaceuticals Limited Neural regeneration peptides and methods for their use
WO2007011595A2 (en) * 2005-07-15 2007-01-25 Neuren Pharmaceuticals Limited Neural regeneration peptides and antioxidants protect neurons from degeneration
JP2009513689A (en) * 2005-10-31 2009-04-02 ラボラトワール セローノ ソシエテ アノニム Use of SDF-1 for the treatment and / or prevention of neurological disorders
ES2433568T3 (en) * 2007-10-17 2013-12-11 Curonz Holdings Company Limited Synthetic analogs of neuronal regeneration peptides
WO2013112002A1 (en) * 2012-01-27 2013-08-01 의료법인 성광의료재단 Biomarker for reducing or relieving brain injury symptoms
AU2013293645B2 (en) * 2012-07-27 2018-04-12 Curonz Holdings Company Limited Method of treating optic nerve damage, ophthalmic ischemia or ophthalmic reperfusion injury
US20160031937A1 (en) * 2013-03-08 2016-02-04 Curonz Holdings Company Limited Neural regeneration peptides and uses therefor
RU2016112931A (en) 2013-10-11 2017-11-16 Терикс Фармасьютикалз Лтд. COMPOSITIONS OF NEW PEPTIDES

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262024B1 (en) * 1993-09-01 2001-07-17 Philadelphia, Health And Education Corporation Neuron regulatory factor for promoting neuron survival

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2382982A3 (en) * 2001-08-24 2012-02-22 Neuren Pharmaceuticals Limited Neural regeneration peptide and methods for their use in treatment of brain damage

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6262024B1 (en) * 1993-09-01 2001-07-17 Philadelphia, Health And Education Corporation Neuron regulatory factor for promoting neuron survival

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
CUNNINGHAM ET AL.: "Identification of a survival peptide in medium conditioned by oxidatively stressed cell lines of neurvous system origin", J. NEUROSCI., vol. 18, no. 18, 15 September 1998 (1998-09-15), pages 7047 - 7060, XP002995764 *

Also Published As

Publication number Publication date
EP1685151A4 (en) 2009-04-22
JP2007511210A (en) 2007-05-10
JP5026083B2 (en) 2012-09-12
WO2005042561A2 (en) 2005-05-12
EP1685151A2 (en) 2006-08-02

Similar Documents

Publication Publication Date Title
RU2008116931A (en) APPLICATION OF N-DESMETHYLCLOSAPINE FOR TREATMENT OF NEUROPSYCHIATRIC DISEASES IN PEOPLE
NO20091888L (en) Arylvinyl azacycloalkane compounds and processes for their preparation and use thereof
CN111904962A (en) Pharmaceutical composition containing PDE4 inhibitor and PI3 or dual PI 3-gamma kinase inhibitor
HRP20150375T1 (en) Pyridazinone derivatives
RU2014122858A (en) TREATMENT OF COGNITIVE DISORDERS (R) -7-CHLORO-N- (HINUKLIDIN-3-IL) BENZO [B] THIOPHEN-2-CARBOSAMIDE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS
Wecker et al. Neuronal nicotinic receptor agonists improve gait and balance in olivocerebellar ataxia
WO2003018754A3 (en) Neural regeneration peptide and methods for their use in treatment of brain damage
WO2005042561A3 (en) Neural regeneration peptides and methods of use
JP2016528171A5 (en)
CH696629A5 (en) Drug combination for the treatment of reactive arthritis or bursitis.
WO2006044665A3 (en) Neuroprotective spirostenol pharmaceutical compositions
ATE495750T1 (en) SULFATIDES FOR THE TREATMENT OF AUTOIMMUNE DISEASES
GB2244431A (en) Treatment of age related memory impairment and other cognitive disorders
DK0786998T3 (en) Use of [R- (Z)] - alpha (methoxyimino) -alpha- (1-azabicyclo [2.2.2] oct-3-yl) acetonitrile to reduce amyloid beta-A4 formation in Alzheimer's disease
Song et al. Targeting calcium signaling in Alzheimer's disease: challenges and promising therapeutic avenues
NZ598861A (en) Role of n-2 hydroxy-ethyl-piperazine-n'-2-ethane sulfonic acid (hepes) in pain control and reversal of demyelinization injury
RU2374245C1 (en) Ligand with wide range of simultaneous receptor activity, pharmaceutical composition, method of preparing said composition and medicinal agent
CN111617255B (en) Combination therapy for the treatment of central nervous system disorders
EA200702534A1 (en) APPLICATION OF A BENZOYL DERIVATIVE 3-AMINOCARBAZOLE FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH THE PROTAGLANDINE E2 (PGE2) PRODUCT
ES2252974T3 (en) USE OF TGF-BETA INHIBITORS TO TREAT BRAIN DISORDERS.
Zhao et al. Ganoderma lucidum spore powder modulates Bcl-2 and Bax expression in the hippocampus and cerebral cortex, and improves learning and memory in pentylenetetrazole-kindled rats**★
DE69800906D1 (en) Use of olanzapine in the manufacture of a medicament for the treatment of cerebral focal ischemia
RU2802972C2 (en) Pharmaceutical combination of atypical antipsychotic and nmda modulator for treatment of schizophrenia, bipolar disorder, cognitive disorder, and clinical depression
RU2006107649A (en) 2-ALKYLIDEN-19-NOR-VITAMIN D DERIVATIVES FOR THE TREATMENT OF WEAKNESS, MUSCLE OR SARCOPENIA
RU2002119776A (en) A method for the treatment of patients with a persistent vegetative state

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2006538375

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004800514

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004800514

Country of ref document: EP